Comments to FDA: Adverse Event Reporting Share page: Docket Number: 2007D-0388 and 2007D-0386 CHPA appreciates the opportunity to provide comments on FDA’s draft guidance for industry on adverse event reporting for dietary supplements and nonprescription human drug products marketed without an approved application. Download Document Issues: OTC Medicines Dietary Supplements Related Posts Polibrief Per-and Polyfluoroalkyl Substances (PFAS) Nov 20, 2024 Polibrief Over-the-Counter Drug Cosmetic Products Nov 20, 2024 Polibrief OTC Contraceptives Nov 20, 2024